INV-101

Innovo Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	INV-101
Sponsor	Innovo Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study (PHASE1)
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects (PHASE1)
First in Human, Single Ascending Dose Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INV-101 CI brief — competitive landscape report
INV-101 updates RSS · CI watch RSS
Innovo Therapeutics, Inc. portfolio CI